The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.

Darcy B PoolerDylan B NessJohn SarantopoulosNicholas SquittieriShoba RavichandranCarolyn D BrittenRavi K AmaravadiUlka VaishampayanPatricia LoRussoGeoffrey I ShapiroAnthony J OlszanskiRaymond P PerezMartin GutierrezMark Allen O'RourkeVincent ChungJames J LeeLionel D Lewis

Published in: British journal of clinical pharmacology (2020)

Sonidegib dosed orally at 800 mg QD (higher than the Food and Drug Administration-approved dose) did not impact the PK or pharmacodynamics of warfarin (CYP2C9 probe substrate) or the PK of bupropion (CYP2B6 probe substrate).

Keyphrases

drug administration
atrial fibrillation
direct oral anticoagulants
living cells
venous thromboembolism
quantum dots
oral anticoagulants
structural basis
amino acid
fluorescent probe
single molecule
human health